Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05036980 | Nov 2021 → Apr 2022 | — | Diffusion Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT04808622 | Mar 2021 | — | Diffusion Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00826930 | Mar → May 2009 | malignant glioma | Diffusion Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04573322 | Sep 2020 → Mar 2021 | COVID-19 | Diffusion Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT01465347 | Feb 2012 → Nov 2015 | glioblastoma | Diffusion Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT00725881 | Aug 2008 → Mar 2010 | intermittent vascular claudication | Diffusion Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05079126 | Dec 2021 → May 2022 | interstitial lung disease | Diffusion Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 2 | NCT03763929 | Aug 2019 → Oct 2020 | stroke disorder | Diffusion Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03393000 | Jan 2018 → Nov 2020 | glioblastoma | Diffusion Pharmaceuticals Inc | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trans Sodium Crocetinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00826930 ↗ |
| Known as | TSC | “Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day...” NCT03393000 ↗6“This is a randomized, placebo-controlled, crossover study of Trans Sodium Crocetinate (TSC) in healthy volunteers, age 18-40 (inclusive), exercising at altitude.” NCT05036980 ↗ “In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit.” NCT03763929 ↗ “This is a randomized, placebo-controlled study of Trans Sodium Crocetinate (TSC) in patients with Interstitial Lung Disease (ILD), age 30-85 (inclusive).” NCT05079126 ↗ “Trans sodium crocetinate (TSC) is a synthetic carotenoid that improves the diffusion of oxygen in animal models of ischemia/hypoxia.” PMID 22003000 ↗ Oct 2011 “A new drug, trans sodium crocetinate (TSC), has been developed to enhance the delivery of oxygen to hypoxic tissues.” PMID 27177177 ↗ May 2016 “Trans Sodium Crocetinate (TSC)” NCT00826930 ↗ |
| Modality | Other / unclassified | “Trans sodium crocetinate (TSC) is a synthetic carotenoid that improves the diffusion of oxygen in animal models of ischemia/hypoxia.” PMID 22003000 ↗ Oct 2011 |
| Route | Intravenous | “Patients were randomized to placebo or eight dosing levels of TSC ranging from 0.25 mg/kg to 2.0 mg/kg given intravenously once daily for 5 days.” PMID 22003000 ↗ Oct 2011 |